A private hospitals group which specialises in cosmetic surgery, weight loss surgery and medical aesthetics returned to making a pre-tax profit in 2021 after its revenue jumped towards £50m.
Transform Hospital Group, which runs Burcot Hall in Bromsgrove and The Pines in Manchester, has posted a pre-tax profit of £464,514 for the 12 months to December 31, 2021, up from a loss of £607,163 in 2020.
Documents filed with Companies House also show the Manchester-headquartered group's revenue increased from £32.5m to £47.7m over the same period.
READ MORE: More than 32,000 jobs to be created by group owned by billionaire Issa brothers
Its gross profit rose from £15.2m to £20.5m while it recovered from an operating loss of £408,492 to a profit of £1.4m.
Commercial director David Shirra said: "Our focussed commercial and marketing efforts, combined with improved operational effectiveness and new agile ways of working, have driven diversification in our service offering and improved utilisation of our facilities.
"However, we have also continued our growth trajectory in our core markets of cosmetic surgery and bariatric surgery.
"Our financial results are encouraging and while our growth is set to continue throughout 2022 and into 2023 and beyond, we measure our success on more than just financials.
Most Read
"For us, the priority is sustaining success and that depends on the quality of the work we do and how we interact with our customers.
"Our TrustPilot ratings across our brands continue to strengthen, now sitting at a minimum 4.5/5 ‘excellent’ score, and we are investing in areas that help us to better serve our patients, such as telemedicine.
"Success also rests on our ability to continue developing in new areas, and our expansion into more general healthcare is indicative of this, as is the recent launch of our B2B Electiva brand, which has seen us extend our services further to NHS trusts and independent healthcare providers."
Clinical services director Christine Mozzamdar added: "We have made significant investment in order to support diversification in the treatments we are able to provide, both in recruitment and in the development of new clinical competencies.
"At the same time, our regulatory performance has continued to improve markedly year on year.
"Demand for our core services has now returned to pre-pandemic levels and we have been able to strengthen our market position.
"Continuing to own this space, coupled with our roadmap to develop new areas of our business, leads us on the path to significant overall growth."